Hervé Maisonneuve - Concepedia

Author

Hervé Maisonneuve

Centre Hospitalier Départemental Vendée ORCID

Also Known As

H Maisonneuve, H. Maisonneuve, Herve Maisonneuve, Hervé Maisonneuve, Hervé Maisonneuve, M. A. Desailly

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Centre Hospitalier Départemental Vendée Inserm Roche (France)Centre Hospitalier Universitaire de Nantes Assistance Publique – Hôpitaux de Paris

About

Hervé Maisonneuve is an author at Centre Hospitalier Départemental Vendée specializing in medicine, oncology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	15	656
2	Health Sciences	3	3	45
3	Natural Sciences	1	1	28
4	Allergy	1	1	12
5	Biochemistry	1	1	28

Hervé Maisonneuve

Publications

2.2K

Citations

H-Index

Page 1

	Year	Citations
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, The Lancet	2018	707
High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years Emmanuel Gyan, Charles Foussard, Philippe B. Bertrand, Blood	2008	153
Nitazoxanide in the Treatment of Taenia Saginata and Hymenolepis nana Infections Jean François Rossignol, Hervé Maisonneuve American Journal of Tropical Medicine and Hygiene Antiparasitic AgentMedicineT. SaginataH. Nana InfectionTaenia Saginata	1984	133
CD38 expression and secondary 17p deletion are important  prognostic factors in chronic lymphocytic leukaemia Patrice Chevallier, Dominique Penther, Hervé Avet‐Loiseau, British Journal of Haematology Hematological MalignancyLymphoid NeoplasiaChronic Lymphocytic LeukaemiaMedicineMixed-phenotype Acute Leukemia	2002	126
The Lymphoid Variant of Hypereosinophilic Syndrome Guillaume Lefèvre, Marie‐Christine Copin, D. Staumont‐Sallé, Medicine	2014	121
Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial Stéphane Leprêtre, Thérèse Aurran, Beatrice Mahé, Blood	2012	92
VELCADE/Dexamethasone (Vel/Dex) Versus VAD as Induction Treatment Prior to Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM): An Interim Analysis of the IFM 2005-01 Randomized Multicenter Phase III Trial. Jean‐Luc Harousseau, Gérald Marit, Denis Caillot, Blood	2006	74
Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older Lucie Obéric, Frédéric Peyrade, Mathieu Puyade, Journal of Clinical Oncology	2021	70
CSF1R and BTK inhibitions as novel strategies to disrupt the dialog between mantle cell lymphoma and macrophages Antonin Papin, Benoît Tessoulin, Céline Bellanger, Leukemia InflammationBtk InhibitionsLymphoid NeoplasiaCancer ImmunosurveillanceMantle Cell Lymphoma	2019	65
Albendazole: placebo-controlled study in 870 patients with intestinal helminthiasis Jean François Rossignol, Hervé Maisonneuve Transactions of the Royal Society of Tropical Medicine and Hygiene	1983	58

Page 1